Conceived and designed the experiments: MFL ZQB DXL. Performed the experiments: LY LZ JL WW CL QFZ FSZ XJW. Analyzed the data: LY LS MFL. Contributed reagents/materials/analysis tools: MFL CL. Wrote the paper: LY CJ MFL.
SFTS virus (SFTSV) is a newly discovered pathogen to cause severe fever with thrombocytopenia syndrome (SFTS) in human. Successful control of SFTSV epidemic requires better understanding of the antigen target in humoral immune responses to the new bunyavirus infection.
We have generated a combinatorial Fab antibody phage library from two SFTS patients recovered from SFTSV infection. To date, 94 unique human antibodies have been generated and characterized from over 1200 Fab antibody clones obtained by screening the library with SFTS purified virions. All those monoclonal antibodies (MAbs) recognized the nucleocapsid (N) protein of SFTSV while none of them were reactive to the viral glycoproteins Gn or Gc. Furthermore, over screening 1000 mouse monoclonal antibody clones derived from SFTSV virions immunization, 462 clones reacted with N protein, while only 16 clones were reactive to glycoprotein. Furthermore, epitope mapping of SFTSV N protein was performed through molecular simulation, site mutation and competitive ELISA, and we found that at least 4 distinct antigenic epitopes within N protein were recognized by those human and mouse MAbs, in particular mutation of Glu10 to Ala10 abolished or significantly reduced the binding activity of nearly most SFTS patients derived MAbs.
The large number of human recombinant MAbs derived from SFTS patients recognized the viral N protein indicated the important role of the N protein in humoral responses to SFTSV infection, and the critical epitopes we defined in this study provided molecular basis for detection and diagnosis of SFTSV infection.
Severe fever with thrombocytopenia syndrome (SFTS), with average case fatality rate of 12%, is an emerging infectious disease caused by a newly discovered virus, named SFTS virus (SFTSV)
SFTSV was classified in the genus
In this report, we for the first time described the generation and characterization of a panel of human monoclonal antibodies (MAbs) against SFTSV N protein using phage display library approach, and the targeted antigenic epitopes were further mapped by competitive assay, molecular modeling and site-directed mutations. The results provided in this study could facilitate understanding of humoral responses to SFTSV infection and help to develop diagnostic tools for detection and diagnosis of SFTSV infection at various infection stages, which could be ultimately applied in clinical work as well as epidemic surveillance.
The origin and preparation of SFTSV have been described earlier
The procedures of phage display library in the vector pComb 3H followed the methods described previously
After three rounds of phage panning, individual clones from enriched phage pools were analyzed by ELISA against SFTS virions or purified N protein. The positive human Fab clones were sequenced and aligned with the DNAPLOT program for alignment to the VBASE database. The human Fab antibodies selected based on binding activity and sequence variance were converted to human IgG by cloning the Fab genes into baculovirus expression cassette vectors, expressed in SF9 cells, and finally purified with protein A column (GE Healthcare, Sweden) for further characterization and functional analysis. Rabbit polyclonal and mouse monoclonal antibodies against N protein were produced commercially by AbMax Biotechnology company (China). The protocols for animal tests were reviewed and approved by animal care committee of China CDC.
The N protein gene from S segment of SFTSV strain HB29 with His tag was cloned into vector pET30a (Novagen, Madison, USA) and expressed in
IFA was performed on different cells according to the experimental design. Vero-E6 cells infected with SFTSV were used to measure the reactivity of MAbs for viral antigens. The SFTSV N protein or glycoprotein (Gn and Gc) genes were separately cloned into baculovirus vector pAc-UW51 and expressed with recombinant baculovirus/SF9 (ATCC CRL-1711) cells system, the expression of N protein or glycoprotein was confirmed by SFTS patient sera. The N protein or Glycoprotein expressing SF9 cells were used to determine the viral protein binding specificity of human or mouse monoclonal antibodies gained in this study. To measure the binding activity of site-directed mutations, 293T cells were grown to 80%–90% confluence and transfected with pCDNA-N plasmid, using the FuGene reagent (Roche). The cells were washed and fixed on glass slides with acetone. Human or mouse MAbs were incubated for 30 min at 37°C, and bound antibodies were detected by FITC-conjugated goat anti-human or anti-mouse antibody (Sigma), and visualized under immunofluorescence microscope.
The viral proteins from purified SFTS virions were separated by SDS-PAGE under reducing conditions, and transferred to a PVDF membrane. After blocking with PBST (0.01 M PBS with 0.1% Tween-20, pH 7.4) containing 1% BSA for 1 h at room temperature, the membrane-immobilized proteins were probed by purified human MAbs (20 µg/ml) or 1∶50 diluted mouse MAbs from hybridoma ascites overnight at 4°C. Monoclonal goat anti-human or anti-mouse antibody (Sigma) was used as secondary antibody. The bands were visualized by 3, 3′ diaminobenzidine (DAB) according to the manufacturer’s instructions.
The microneutralization assay was performed as previously described
A panel of extensive competition experiments was developed to evaluate the binding specificity of MAbs and determine whether these MAbs bind to distinct sites in N protein. Purified SFTSV N protein was used as coating antigen in 0.05 M bicarbonate buffer (pH 9.6) and incubated overnight at 4°C. After blocking the plate with PBST containing 1% BSA for 1 h at 37°C, human or mouse MAbs were dissolved in PBS and added into each well by 50 µl in continuous series 2-fold dilution to prepare a concentration gradient of competitors. Then 50 µl HRP-MAbs was then added into each well at a previously decided concentration known to give 90% of the maximum absorbance value on N antigen. After incubation, 3, 3′, 3, 5′ -tetramethylbenzidine (TMB) was added, and absorbance was measured at 450 nm. Percent of binding inhibition of labeled antibodies was calculated according to the formula:
The computational simulation was carried out using Discovery studio 2.0 (Accelrys, San Diego, CA)
A set of site-specific mutations were generated using QuickChange II site-directed mutagenesis kit (stratagene, La Jolla, CA) for PCR using manufacturer’s guidelines. The truncation mutations of N protein were generated from the N-terminal or C-terminal end by every 5 amino acids. All mutations were generated using pCDNA5.0 plasmid as a template. All constructs were transfected to 293T cells for transient expression, and the mutations were analyzed by IFA assay described above for binding activity with human and mouse MAbs.
According to the medical research regulation of Ministry of Health, all studies involved in human samples were reviewed and approved by the ethics committee of China CDC, which uses international guidelines to ensure confidentiality, anonymity, and informed consent. The written informed consent was agreed by the patients. The protocols for animal tests have been approved by animal care committee of China CDC.
Using the pComb 3H vector system, the SFTSV patients derived light chain library was first constructed with a complexity of >1.0×107 clones, the Fd heavy chain genes were efficiently inserted into the light library vectors and finally resulted in a initial combinatorial Fab library with a complexity of >1.0×108 independent clones and 100% Fab genes diversity after sequencing confirmation. After three rounds of phage panning against purified SFTS virions, we selected more than 1200 Fab clones, of which 475 clones showed positive reaction to SFTS virions. However, all 475 clones were only reactive to the purified N protein tested by ELISA and IFA. To select human antibodies to SFTSV glycoproteins, we used purified N protein as blockage in another process of phage panning. However, no targeted Fab antibodies against glycoproteins were identified over screened additional 600 Fab clones. In addition to these human recombinant monoclonal antibodies, through screening 1000 mouse MAbs clones derived from immunization with SFTSV virions, 462 clones were identified to react with N protein, while only 16 clones were reactive to glycoprotein Gn or Gc expressed in recombinant baculovirus transfected SF9 cells (
Sequence analysis of all 475 human positive Fab clones revealed the presence of 94 unique ones. Using the DNAPLOT program for alignment to the VBASE database
The phylogenetic tree was based on amino acid sequence in the variable regions of light chains. Among the 94 human Fab clones, 82 clones in purple represent human germline genes as specified by the VK1 family, 2 belong to VK3 family, 4 belong to VL1 family, 1 belongs to VL2 family, and 5 belong to VL3 family.
| Fab clonesb | CDR1 | CDR2 | CDR3 |
| H2A12 | SYSMN | SISSSSSYIYYADSVKG | EDYGL*****LDY |
| H2B10 | ----- | ----------------- | -T---*****--- |
| H2A1 | ----- | ----------------- | -S--P*****--- |
| H4G1 | ----S | -----R----------- | -T---*****--- |
| H2D3 | ----- | ----G------------ | -S--P*****I-- |
| H2F8 | ----- | ----GGN---------- | -S--P*****--- |
| H4D9 | ----- | ----R------------ | -T--P*****--- |
| H4B7 | ----- | ----G------------ | -L--N*****--- |
| H4A4 | ----- | ----G------------ | DS-H-*****F-- |
| H2B8 | ----- | ----G------------ | DL--P*****--- |
| H2C11 | ----- | ----G------------ | DS--V*****-G- |
| H4C1 | ----- | ----G------------ | DN--I*****F-- |
| H2C2 | ----- | ----G------------ | D---V*****S-V |
| H2C10 | ----- | ----R------------ | DN--I*****F-- |
| H4A6 | T---- | ----R------------ | DN-A-*****M-V |
| H4E12 | ----- | ----N------------ | DS--P*****--V |
| H4E5 | ----- | F---------------- | DT--I*****F-- |
| H4B2 | ----- | ----------------- | D----*****I-- |
| H2D7 | ----S | ----------------- | D---V*****-H- |
| H2F10 | ----- | ----------------- | D---S*****-SA |
| H2D12 | ----- | ----------------- | DN--I*****F-- |
| H4F7 | ----- | ----------------- | DS---*****F-- |
| H4G5 | ----- | ----------------- | DN---*****F-- |
| H2A8 | ----- | ----------------- | DQ--V*****I-- |
| H4E3 | ----- | ----------------- | DL--V*****V-I |
| H4A7 | ----- | ----------------- | -N--V*****I-- |
| H2B4 | ----- | ----------------- | -----*****M-V |
| H2B1 | ----- | ----------------- | -N---*****M-V |
| H2A6 | ----- | ----------------- | DS--I*****M-V |
| H2F5 | ----- | ----------------- | DS--F*****M-V |
| H4G4 | ----- | ----------------- | ----V*****-YV |
| H2A4 | ----- | ----------------- | D---I*****S-- |
| H4C9 | ----- | ----G------------ | RN--E****YS-- |
| H4B3 | ----- | ----G------------ | TPG-IAVAEFM-V |
| H1C2 | ----- | ----------------- | TPG-IAVAEFM-V |
| H2D1 | T---- | ----------------- | TPG-IAVAEFM-V |
| H4C8 | ----- | ----------------- | HFV-ASTH**T-- |
| H2E4 | ----- | ----------------- | GHV-ATD***--- |
| H2F4 | T---- | ----------------- | D---VIR***F-P |
| H4E11 | -S--- | ----GG----------- | GGEYSSG***F-- |
| H5D12 | ----- | ----G------------ | LAA-ASSS**I-- |
| H4B9 | ----- | ----G------------ | TPG-GDYYY*M-V |
| H5A2 | ----- | ----------------- | DL-YGDYV**--- |
| H2H9 | ----- | ----------------- | VT-YGSGSYFF-- |
| H5D7 | --W-H | R-YTDG-STS------- | GSSYYG****M-V |
MAbs labeled were included in further study; b: MAbs derived from SFTS patients were designated as “H” for the first letter, and mouse derived MAbs were designated as “M” for the first letter; -: Indiated the identical to the amino acid sequence of Fab H2A12; *: No amid acid.
Next, above N protein specific Fab antibody clones with unique sequences were selected and converted into IgG molecules based on their sequence diversity and specific N protein binding activity (
A) IFA analysis shows all selected MAbs are reactive to the viral and recombinant N protein. Vero: Vero cells infected by SFTSV strain HB29; Sf9: Sf9 cells expressing recombinant N protein with the baculovirus system; 293T: 293T cells transiently expressing the recombinant N protein. B) Western blot assay of human and mouse MAbs. Most MAbs represented a positive N protein band at 27 KDa, while MAbs H4B9, H4C8, H4E11 and H2H9 showed negative result. R. poly: rabbit polyclonal antibody immunized with the SFTSV N protein.
In order to characterize epitope binding patterns of the 20 human MAbs and 11 mouse MAbs with SFTSV N protein, a set of competitive ELISA experiments were performed. Based on above analysis data, we chose three human MAb H2A12, H2H9,H3E11 and one mouse MAb M1D8 as detective antibody labeled with horseradish peroxidase (HRP), and totally 20 human MAbs and 11 mouse MAbs were used as competing antibodies in the test. As shown in
| MAbs | HRP conjugated MAb (%) | |||
| H2A12 | H2H9 | H3E11 | M1D8 | |
| H2A12 | 93 | 22 | 25 | 12 |
| H2A4 | 75 | 16 | 17 | 21 |
| H2E4 | 80 | 22 | 27 | 31 |
| H2F4 | 77 | 19 | 22 | 25 |
| H1C2 | 78 | 24 | 23 | 14 |
| H4B9 | 80 | 22 | 31 | 11 |
| H4C8 | 82 | 27 | 17 | 12 |
| H4E11 | 80 | 31 | 13 | 11 |
| H2H9 | 32 | 88 | 19 | 12 |
| M7E11 | 88 | 30 | 15 | 32 |
| M3E11 | 20 | 15 | 85 | 19 |
| M1D8 | 20 | 23 | 14 | 90 |
Competing MAbs, SFTS patients derived were designated as “H” for the first letter; and mouse derived were designated as “M” for the first letter.
Percentage of binding inhibition of HRP conjugated detective antibodies in competitive ELISA assay.
Since the epitope recognized by a panel of MAbs represented by H2A12 might be a dominant epitope of SFTSV N protein, we further define potential epitopes on N protein surface recognized by H2A12. We first found an antibody crystal structure 1DFB (PDB) which has as high as 90% sequence similarity with human MAbs H2A12, and use this structure as the model in computer-simulation. The crystal structure of N protein of the rift valley fever virus (RVFV) was selected as model for SFTSV N protein, because RVFV N protein has maximal identity of 41.4% in backbone structures with SFTSV N protein
Computer-simulated docking structure shows 3 representative binding sites on N protein at A) amino acid 8–15, B) amino acid 35–45, and C) amino acid 132–142. D) The scheme represents the regions of site-directed mutations in N protein based on 3D-structure predictions and truncation studies.
Since previous studies on
| Antibodies | WT N | ΔN5 | ΔN10 | ΔC5 | S9Aa | E10Aa | E10A F11Aa | F11Aa | I39Ab | K40Ab | K41Ab | E44Ab | T45Ab | N139Ac | Y140Ac | M141Ac | Y242Ad | R243Ad | N244Ad |
| R. Poly | +++ | +++ | + | + | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | ++ | +++ | +++ | +++ | +++ |
| H2A12e | +++ | +++ | – | – | +++ | + | – | +++ | +++ | +++ | +++ | +++ | +++ | +++ | + | +++ | +++ | +++ | +++ |
| H2A4e | +++ | +++ | – | – | +++ | – | – | +++ | +++ | +++ | +++ | +++ | +++ | +++ | + | +++ | +++ | +++ | +++ |
| H2E4e | +++ | +++ | – | – | +++ | + | – | +++ | +++ | +++ | +++ | +++ | +++ | +++ | + | +++ | +++ | +++ | +++ |
| H2F4e | +++ | +++ | – | – | +++ | – | – | +++ | +++ | +++ | +++ | +++ | +++ | +++ | + | +++ | +++ | +++ | +++ |
| H4B9e | +++ | +++ | – | – | +++ | ++ | – | +++ | +++ | +++ | +++ | +++ | +++ | +++ | + | +++ | +++ | +++ | +++ |
| H4C8e | +++ | +++ | – | – | +++ | – | – | +++ | +++ | +++ | +++ | +++ | +++ | +++ | + | +++ | +++ | +++ | +++ |
| H4E11e | +++ | +++ | – | – | +++ | + | – | +++ | +++ | +++ | +++ | +++ | +++ | +++ | + | +++ | +++ | +++ | +++ |
| H2H9 | ++ | ++ | – | – | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | + | ++ | ++ | ++ | ++ |
| H1C2 | +++ | +++ | – | – | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | + | +++ | +++ | +++ | +++ |
| M7E11e | +++ | +++ | – | – | +++ | + | – | +++ | +++ | +++ | +++ | +++ | +++ | +++ | + | +++ | +++ | +++ | +++ |
| M1D8 | +++ | +++ | – | – | +++ | +++ | +++ | +++ | +++ | – | – | – | +++ | +++ | + | +++ | +++ | +++ | +++ |
| M3E11 | +++ | +++ | – | – | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | +++ | ++ | +++ | +++ | – | +++ |
Single alanine substitution at amino acid positions a5∼15 of N-terminal; bpositions 35∼45; cpositions 132∼142, dpositions 235∼245 of C-terminal. eRefer to major MAbs representing abolished or significantly reduced binding activity to mutation of E10A in N protein; (+) to (+++) indicates the relative intensity of fluorescence. R. Poly: a rabbit polyclonal antibody immunized with the SFTSV recombinant N protein.
In order to address which amino acid sites were critical for MAbs binding and the antigenic epitopes of N protein, single mutations with alanine substitution were performed. For N terminus, single alanine mutations of N terminal 5∼15 amino acid resulted in no change of antibody binding activities, but only the mutation of Glu10 to Ala (E10A) significantly reduced the binding activity of most human MAbs represented by H2A12, and most mouse MAbs represented by M7E11 (
In this study, we for the first time reported the generation and characterization of a panel of human MAbs by using phage display technology. The critical role of N-terminal amino acids for the immunogenicity of SFTSV N protein as well as other 3 antigenic sites were finally defined.
As a newly emerged viral pathogen, successful control of SFTSV epidemic requires a better understanding of antigen targets in humoral immune responses to the infection. Results in this paper presented that intensive antibodies were reactive to the N protein, but less antibodies to viral glycoprotein, which is believed to be major neutralizing antibody inducer. In general, all virus infection should induce neutralizing antibodies, as for bunyavirus infection, it has been largely evidenced that almost all of neutralizing polyclonal or monoclonal antibodies are viral glycoprotein Gn or Gc specific
Critical amino acids for antibody binding are indicated in the modelling structure as the sites they located (Yellow). B) Ramachandran plot of the N protein prediction illustrates that visualized backbone dihedral angles (phi/psi) of amino acid residues in modeling structure are properly validate.
However, the large number of specific antibodies against SFTSV N protein gained in this study also indicated that the N protein played an important role in humoral immune responses to the new bunyavirus infection and the process of affinity maturation
As an emerging infectious disease, epitopes in the N protein of SFTSV has not been identified. In fact, there were few reports on epitopes of viral N proteins even for other members in the
In addition, according to the results of competition assay, at least four distinct antigenic sites were recognized by MAbs, represented by human MAbs H2A12, H2H9, and mouse M3E11, M1D8. Mutation analysis revealed critical amino acid residues for binding with MAbs H2A12 group, M1D8, M3E11, however, the binding sites of H2H9 still remain unclear. Although interface of antigen and antibody is best defined by crystallography, computer-simulated modeling combined with site-directed mutagenesis has been used successfully to define the sites critical for the interaction between antibody and antigen
In summary, we generated and characterized a panel of human MAbs against nucleocapsid protein of SFTS virus derived from SFTSV infected patients using phage display technology. Importantly, localization of at least 4 antigenic sites on nucleocapsid protein recognized by a panel of human MAbs has provided, for the first time, insight into the human antibody responses to SFTS viruses which contribute to the SFTS immunity in the recovered patient. Furthermore, the critical role of N- terminal amino acids for the immunogenicity of SFTSV N protein would help to understand the significance of the defined epitopes and applications for diagnosis of human infection with SFTS virus.
Characterization of mouse MAbs to glycoprotein Gn and Gc by IFA. The antigen slides were made from Vero cells infected with SFTSV strain HB29, or Sf9 cells expressing Gn or Gc protein with infection of recombinant baculovirus. Mouse MAbs represented by 2D5 showed Gn specificity on both Vero and Sf9 cells (Vero-Gn, Sf9-Gn); mouse MAbs represented by M1G8 showed Gc specificity on both Vero and Sf9 cells (Vero-Gc, Sf9-Gc).
(TIF)
Click here for additional data file.
IFA and western blot assay of truncated N protein from the 293T lysate with rabbit polyclonal antibody. The intact N and truncated N proteins were transiently expressed in 293T cells and the cells tested by IFA (A) with R. poly antibodies showed a positive reactivity to the intact N and truncated △N5, and a weak intensity of fluorescence to truncated △N10 and △C5 proteins. The cell lysates were used for western blot assay of above truncated N protein and showed all positive reactivity (B). R. poly: A rabbit polyclonal antibody immunized with the SFTSV N protein; N: The intact N protein transiently expressed in293T cells; △N5, △N10 and △C5: Truncation of 5, 10 amino acids at the N- or C-terminus of N protein; NC: Normal 293T cells as negative control.
(TIF)
Click here for additional data file.
Neutralization activity of human and mouse MAbs against SFTSV tested by micro-neutralization test.
(DOC)
Click here for additional data file.